The American Society of Clinical Oncology (ASCO) recently published a clinical practice guide for the vaccination of human papillomavirus (HPV) vaccine for the prevention of cervical cancer. This is the first guideline for primary prevention of cervical cancer in various regions of the world with different levels of socio-economic and structural resources and environment, providing evidence-based guidance for health care providers all over the world.

The guide includes four levels of recommendations based on resource settings: basic, limited, enhanced and maximum. Levels involve financial resources in a country or region, as well as their health systems, including personnel, infrastructure and access to services. The guide supplements the two other cervical cancer guidelines for ASCO and also delamination into these four resource levels.

Main guidance recommendations:

For girls aged 9 to 14, two doses of HPV vaccine were recommended, at least 6 months between two doses and up to 12 to 15 months.

HIV positive girls should receive three doses.

For maximum and enhanced resource settings:

If girls over 15 years of age receive first dose before they are 15, they can complete a two - dose series.

If they did not receive the first dose before the age of 15, they should receive three doses.

In these two cases, the vaccine can be vaccinated at the age of 26.

For limited and basic resource settings, if the girls aged 9 to 14 have enough resources after vaccination, girls who receive a dose of drugs may receive additional doses between 15 and 26 years old.

Boys vaccination: in all cases, if there are at least 50% coverage and enough resources in the female target population, boys can be vaccinated, and this vaccination is effective.

So, in the case of adequate resources, regardless of sex, whether or not before or after 26 years of age, the HPV vaccine should be injected.

Cervical cancer is the fourth most common cancer among women in the world, and the prevalence rate is disproportionate in the less developed areas. In fact, 85% of the diagnosis of cervical cancer and 87% of the death of cervical cancer occur in less developed areas, including parts of Africa and Latin America.

.

Silvia deSanjos&eacute, CO chair of the panel of experts, said: "because resource availability is quite different within the country, we need to adjust strategies to improve HPV vaccination."

Catal&agrave, d'Oncologia cancer epidemiology research program: "this guideline is unique in providing recommendations for cervical cancer vaccination, which can adapt to different resource levels, and we expect that it will have a significant impact on the global health community".

HPV infection is almost the cause of all cervical cancer in the world. Although it may also lead to genital warts and some other cancers, cervical cancer is the most common and serious disease associated with HPV> infection so far. Unlike other existing HPV vaccination guidelines, the ASCO guide focuses on the use of HPV inoculation, specifically for the prevention of cervical cancer.

"Although the HPV vaccine has been in existence for more than 10 years, but in many places, including in the United States and other high resource countries, vaccine uptake is not ideal, the expert group to develop the guidelines, and the Argentina Buenos Aires National Cancer Institute officials and researcher Silvina Arrossi said:" as a cancer doctor, ASCO will continue to support HPV vaccination programs, and efforts to help the world more women accept this difficult cancer".

Shared with the American Society of Clinical Oncology (ASCO)